ACET - Adicet Bio, Inc.

8.22
0.170   2.068%

Share volume: 187,402
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.19%

PREVIOUS CLOSE
CHG
CHG%
$8.05
0.17
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 40%
Dept financing 22%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
17.43%
1 Month
16.27%
3 Months
4.05%
6 Months
731.31%
1 Year
1,346.16%
2 Year
321.54%
Key data
Stock price
$8.22
P/E Ratio 
N/A
DAY RANGE
$8.15 - $8.47
EPS 
-$5.37
52 WEEK RANGE
$0.46 - $9.05
52 WEEK CHANGE
$1,346.16
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
9.596 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$222,359
AVERAGE 30 VOLUME 
$149,747
Company detail
CEO: Chen Schor
Region: US
Website: adicetbio.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.

Recent news